SCHEMBL5562415

SCHEMBL5562415

CC(c1ccc2cc(-c3cc(-c4ccncc4)n[nH]c3=O)n(C(=O)O)c2c1)C1CCCCN1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
PAX8 Q06710 1/20 0.32
ATM Q13315 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
BRAF P15056 1/20 0.32
RPS6KA2 Q15349 3/20 0.31
RPS6KA3 P51812 1/20 0.31
ROCK2 O75116 1/20 0.31
DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1751356 0.90 BRD4 (0.35) SLC6A3SLC6A2SLC6A4
SCHEMBL5562332 0.84 ALDH1A1 (0.34) SLC6A3SLC6A2SLC6A4CYP2D6MAPK1
SCHEMBL5562421 0.79 DRD2 (0.34) CYP1A2CYP2D6MKNK1MKNK2RPS6KA2
SCHEMBL1750984 0.75 GPR119 (0.34) SLC6A3SLC6A2SLC6A4
SCHEMBL5563089 0.72 MME (0.35) MAPTRPS6KA2RPS6KA3ROCK2
SCHEMBL5562424 0.71 DRD2 (0.42) CYP1A2
SCHEMBL1751355 0.71 NR1H2 (0.35)
SCHEMBL5562322 0.65 MKNK1 (0.32) CYP1A2CYP2D6MKNK1
SCHEMBL8273868 0.64 CDK5 (0.35) MAPK1ROCK2
SCHEMBL1750400 0.63 NR1H2 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751141-A1 NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 Aventis Pharma S.A. (FR) 2007-02-14 EP disclosed
WO-2005111019-A1 NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 AVENTIS PHARMA S.A. (FR) 2005-11-24 WO disclosed